<?xml version="1.0" encoding="UTF-8"?>
<p>Antiviral therapies may have significant drug-drug interactions with antiplatelet agents and anticoagulants in patients with prior cardiovascular disease. Medications now in investigation of COVID-19 treatment such as lopinavir/ritonavir, remdesivir, tocilizumab, or sarilumab that were metabolized by CYP3A4 should be cautious when P2Y12 Platelet receptor inhibitors used simultaneously in patients with cardiovascular disease.
 <sup>
  <xref rid="R24" ref-type="bibr">24</xref>
 </sup>
</p>
